acssart glp 1 reviews GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events SymptoGuard®: Relief from GLP-1 Side

Large-scale clinical trials have demonstrated that GLP-1RAs reduce the incidence of major adverse cardiovascular events (MACE), including myocardial infarction (MI) and stroke, through metabolic, anti-inflammatory, and direct cardiac mechanisms in both diabetic and non-diabetic populations [316318]

Some patients reach their goal weight by month 6

Perova T, Wasserman MJ, Li PP, Warsh JJ

Due to its longer half-life comparing to glucagon-like peptide 1 (GLP), the endogenous ligand of GLP-1R, exendien-4 has better and longer-lasting effects on promoting glucose-dependent insulin secretion [1, 3, 4, 5, 6]

The clinical trials needed to establish safety and efficacy in this population are still underway